Summer 2026

Quality Data Analyst Intern

Posted on 5/16/2026

Tandem Diabetes Care

Tandem Diabetes Care

1,001-5,000 employees

Develops subcutaneous insulin pumps and software

Compensation Overview

$30 - $41/hr

No H1B Sponsorship

San Diego, CA, USA

Hybrid

Hybrid role; on-site required in San Diego, CA.

Category
Data & Analytics (1)
Required Skills
Power BI
Minitab
Python
SQL
ETL
Tableau
Data Governance
Databricks
Data Analysis

Get referred to Tandem Diabetes Care

See people who can refer or advise you

Requirements
  • Experienced with MS Office (Word, Excel, Outlook, PowerPoint) and effectively use MiniTab or other applicable statistical software.
  • Possess analytical skills and the ability to work independently.
  • Good organizational skills with the ability to prioritize workload.
  • Able to effectively convey information related to work product in one on one conversation or in a group.
  • Able to work effectively in a team environment.
  • Strong analytical and problem-solving skills. Able to present analysis to various stakeholders.
  • Technical knowledge of database and reporting tools.
  • Experience creating interactive dashboards using tools like Power BI or Tableau.
  • Experience with extracting, transforming, and loading data from various data sources into a single data report.
  • Coding skills in languages such as SQL, Python, or equivalent. Experience with Databricks is a plus.
  • Strong knowledge and application of principles outlined in Good Manufacturing Practices (GMP).
  • Capable of producing, interpreting and analyzing results using statistical methodology, including control charts.
  • Able to assert own ideas and persuade others through effectively consolidating, evaluating, and presenting relevant information.
  • Experience working with large datasets and performing data analysis using statistical methods.
  • Continuously monitor and initiate improvement opportunities with data quality and integrity.
  • Adept at seeing change as an opportunity to improve business performance.
  • Excellent verbal and written communication skills and flexibility to function in a fast paced and innovative environment.
  • Knowledge of data governance and data security best practices.
  • Able to alter behavior and opinions in light of new information.
  • Knowledge of problem solving methodologies: 5 why’s analysis, Cause and Effect diagrams, etc.
Responsibilities
  • Partners with Quality Engineering and cross-functional team members to conduct data analysis reports to support post market risk management activities, product monitoring and quality investigations.
  • Define and implement Power BI dashboards, reports and analyses associated with post market surveillance data and metrics that can make data and insights more easily available to non-technical stakeholders.
  • Works with Business Intelligence and IT team members to develop and implement IT solutions to support the company’s analytics needs.
  • Collaborates with others in Operations, R&D Quality, Customer Technical Support, Clinical Evaluation, Failure Investigation, Risk Management, Global Post Market Surveillance and other internal groups.
  • Quality Data Analyst Interns are also responsible for: Collaborates with stakeholders across Tandem’s business units to provide scalable reporting and analytics solutions associated with post market surveillance data.
  • Creates interactive and automated Power BI dashboards and data reports.
  • Collaborate with data scientists, data engineers, and other IT professionals to deliver comprehensive data solutions and reports to increase data analysis efficiencies.
  • Provides ad-hoc analyses and written reports as needed.
  • Participates in problem definition and user needs gathering with project teams and business process owners.
  • Facilitates and participates on cross-functional process improvement teams to drive operational quality excellence and cost savings initiatives.
  • Trains cross-functional stakeholders on data use and access.
  • Enables non-technical stakeholders to quickly answer key questions and make better and faster decisions through easy access to data and analytics tools.
  • Assists in incorporating data from multiple sources including product, ERP, CRM, and other business applications to present consolidated views of post market surveillance data.
  • Confirms completion of required training plan before assuming job responsibilities.
  • Ensures compliance with company policies, including Privacy/HIPAA, and other legal and regulatory requirements.
  • Other responsibilities as assigned.
  • Performs other duties as assigned.
  • Minimum experience items relocated into responsibilities:
  • Assists in collecting, cleaning and validating data from multiple sources
  • Support the development and maintenance of dashboards, reports, and visualizations
  • Perform basic data analysis to identify trends, patterns and anomalies
  • Help document business definitions, metrics and reporting logic
  • Support enhancements to existing dashboards and reports
  • Assist with testing and validation of reports to ensure data accuracy and consistency
  • Help maintain data quality and reporting standards
  • Work with cross functional teams to understand business requirements
  • Support ad-hoc reporting and analysis requests
  • Assist in preparing presentation materials and summaries for process stakeholders
  • Help document process workflows
  • Support continuous improvement initiatives related to analytics and reporting efficiency
  • Assist in defining and validating key performance indicators
  • Perform QA checks to validate data accuracy
Desired Qualifications
  • Completion of Junior year in Science or Engineering or a related field, preferred
  • Intern experience in related environment, preferred

Tandem Diabetes Care designs and sells insulin pumps and related software for people with diabetes. Its flagship product is the t:slim X2 insulin pump, a subcutaneous device that delivers insulin and can work with other diabetes management devices through interoperable technology. A key feature is Basal-IQ, which uses continuous glucose monitoring data to predict low blood sugar and pause insulin delivery to prevent hypoglycemia. The company generates revenue from selling pumps and accessories like infusion sets and cartridges, as well as software updates and subscriptions for advanced management features, creating recurring income. Tandem differentiates itself with interoperable hardware and software that aim to simplify diabetes care and integrate with other devices, not just sell a single pump. Its goal is to improve diabetes management and quality of life by providing user-friendly, connected insulin delivery and management solutions for patients aged six and older.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

2006

Get referred to Tandem Diabetes Care

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $254.6 million, up 5.8%, with guidance reaffirmed.
  • Gross margin improved to 56%-57% guidance, aided by pharmacy mix and operating leverage.
  • Control-IQ+ pregnancy clearance opens a high-trust niche and expands prescriber enthusiasm.

What critics are saying

  • TruSteel supply constraints from Convatec persist through 2026, threatening shipments and customer retention.
  • Mark Novara's May 18, 2026 commercial exit weakens execution during the pharmacy transition.
  • Pharmacy pay-as-you-go shifts revenue timing, creating a 2026 sales headwind and longer payback.

What makes Tandem Diabetes Care unique

  • Control-IQ+ gained FDA pregnancy clearance on April 27, 2026, first in U.S.
  • Tandem Mobi and t:slim X2 share remote-updatable automated insulin delivery software.
  • Mobi Tubeless uses one platform for tubed and tubeless wear, filed Q2 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Holidays

401(k) Company Match

Remote Work Options

Hybrid Work Options

Employee Stock Purchase Plan

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Yahoo Finance
Aug 6th, 2026
Tandem Diabetes Q2 revenue hits $254.6M, meets expectations with 5.8% growth

Tandem Diabetes Care met Wall Street's revenue expectations in Q2 2026, reporting sales of $254.6 million, up 5.8% year on year. The diabetes technology company's GAAP loss of $0.31 per share aligned with analyst estimates. The company reaffirmed its full-year revenue guidance of $1.08 billion at the midpoint, close to analyst forecasts. Adjusted EBITDA of $6.42 million beat expectations by 82.2%, with a 2.5% margin. Operating margin improved to -5.4%, up from -21.5% in the same quarter last year. However, free cash flow was -$38.67 million, compared to -$15.7 million in Q2 2025. Analysts expect revenue to grow 9.3% over the next 12 months. Over the past five years, Tandem Diabetes has grown sales at an 11.5% compounded annual growth rate.

MarketBeat
Jul 30th, 2026
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) given consensus rating of "Hold" by analysts.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) given consensus rating of "Hold" by analysts. July 30, 2026 Key points. * Analysts rate Tandem Diabetes Care "Hold" overall: Of 22 firms, 11 recommend holding, nine recommend buying, one strongly recommends buying, and one recommends selling. The average 12-month price target is $28.73. * Recent analyst actions were mixed, with TD Cowen raising its target to $28 while Bank of America and Citigroup cut targets to $25 and $17, respectively. * Tandem reported better-than-expected quarterly results, including an adjusted loss of $0.30 per share versus the $0.46 expected and revenue of $247.2 million, up 5.5% year over year. Shares opened at $18.59, while several institutional investors recently established or expanded positions. * Interested in Tandem Diabetes Care? Here are five stocks we like better. Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Get Free Report) has been assigned a consensus recommendation of "Hold" from the twenty-two research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation, nine have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $28.7250. TNDM has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft started coverage on shares of Tandem Diabetes Care in a research note on Tuesday, June 23rd. They issued a "hold" rating and a $15.50 target price for the company. TD Cowen restated a "buy" rating and set a $28.00 price target (up from $25.00) on shares of Tandem Diabetes Care in a research note on Monday, April 20th. Bank of America decreased their price target on shares of Tandem Diabetes Care from $35.00 to $25.00 and set a "neutral" rating for the company in a report on Monday, May 18th. Benchmark assumed coverage on shares of Tandem Diabetes Care in a research note on Monday, May 11th. They set a "hold" rating for the company. Finally, Citigroup reissued a "neutral" rating and set a $17.00 price objective (down from $22.00) on shares of Tandem Diabetes Care in a report on Thursday, May 28th. Institutional trading of Tandem Diabetes Care. A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Freestone Grove Partners LP acquired a new position in shares of Tandem Diabetes Care in the third quarter valued at about $22,706,000. First Light Asset Management LLC purchased a new position in shares of Tandem Diabetes Care in the fourth quarter worth about $23,947,000. BNP Paribas Financial Markets lifted its holdings in shares of Tandem Diabetes Care by 468.5% during the fourth quarter. BNP Paribas Financial Markets now owns 1,248,481 shares of the medical device company's stock worth $27,442,000 after purchasing an additional 1,028,866 shares during the period. Marshall Wace LLP acquired a new stake in shares of Tandem Diabetes Care during the fourth quarter worth about $19,244,000. Finally, Defilade Capital Management L.P. purchased a new stake in Tandem Diabetes Care in the first quarter valued at approximately $14,606,000. Tandem Diabetes Care trading up 4.7%. Tandem Diabetes Care stock opened at $18.59 on Thursday. The stock has a 50-day moving average of $16.36 and a two-hundred day moving average of $18.92. The company has a debt-to-equity ratio of 4.54, a quick ratio of 3.07 and a current ratio of 3.58. Tandem Diabetes Care has a one year low of $9.98 and a one year high of $29.65. The stock has a market cap of $1.27 billion, a PE ratio of -13.28 and a beta of 1.58. Discover more Cryptocurrency News investment Stock Screener Tool Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The medical device company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.46) by $0.16. Tandem Diabetes Care had a negative return on equity of 53.88% and a negative net margin of 9.20%.The business had revenue of $247.22 million for the quarter, compared to analyst estimates of $240.41 million. During the same quarter in the previous year, the firm earned ($0.66) earnings per share. The company's revenue was up 5.5% on a year-over-year basis. On average, research analysts anticipate that Tandem Diabetes Care will post -0.72 EPS for the current fiscal year. About Tandem Diabetes Care. Tandem Diabetes Care, Inc NASDAQ: TNDM, headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim(R) Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities. The company's flagship offering, the t:slim X2(R) Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Tandem Diabetes Care, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tandem Diabetes Care wasn't on the list. While Tandem Diabetes Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Yahoo Finance
Jul 16th, 2026
Tandem Diabetes shares fall 16% despite Q1 revenue beating estimates by 3.2%

Tandem Diabetes reported Q1 revenues of $247.2 million, up 5.5% year on year and beating analysts' expectations by 3.2%. The company also beat earnings per share estimates, whilst full-year revenue guidance met analyst expectations. Despite the strong quarter, the stock has fallen 16.1% since reporting and now trades at $15.50. Investor expectations may have been higher than Wall Street's published projections. The healthcare technology sector overall reported a strong Q1, with the seven stocks tracked beating revenue consensus estimates by 1.6%. Next quarter's revenue guidance came in 2.8% above expectations. Healthcare technology shares have risen 21.9% on average since the latest earnings results. The sector benefits from healthcare digitalisation, regulatory incentives, and labour shortages driving automation demand. However, it faces challenges including lengthy sales cycles, complex regulatory requirements, and integration difficulties with legacy systems.

MedTech Dive
Jul 7th, 2026
Top diabetes tech stories from the first half of 2026.

Top diabetes tech stories from the first half of 2026. Multi-analyte sensors, insulin patch pumps and regulatory actions have led diabetes tech news in 2026. Here are some highlights of MedTech Dive's coverage. Published July 7, 2026 It's been a busy year for the diabetes technology space, with companies unveiling new technologies, developing products to match their rivals and grappling with regulatory actions that have highlighted quality concerns. At the beginning of the year, the Food and Drug Administration issued a string of warning letters to Abbott, Beta Bionics and Unomedical over quality issues with continuous glucose monitors and insulin pumps. Dexcom disclosed some CGMs it had discarded were stolen and being resold. Companies also announced plans for new diabetes devices and aspirations for expanded insurance coverage. Abbott received a CE mark for a dual glucose-ketone sensor, intended to help people with diabetes avoid a serious complication called diabetic ketoacidosis. Multiple insulin pump makers, including Insulet and MiniMed, discussed plans to design fully closed loop automated insulin delivery systems, which would allow people to manage their diabetes without meal announcements or bolus insulin doses. Meanwhile, Tandem Diabetes Care and Beta Bionics announced timelines for tubeless insulin pumps, which would position them to compete with market leader Insulet. Here are the top stories from the first half of the year. * 4 diabetes tech execs on the future of multi-analyte glucose sensors By Elise Reuter - June 22, 2026 Executives with Abbott, PercuSense and Biolinq spoke with MedTech Dive about what's next with multi-analyte sensor technology. Read the full article | * Diabetes tech companies are racing toward 'fully closed loop' devices. But automation comes with trade-offs. By Elise Reuter - June 4, 2026 Insulet, MiniMed and Tandem Diabetes Care are all working on systems to take meal announcements out of diabetes management. Read the full article | * Abbott receives CE mark for dual glucose-ketone sensor By Elise Reuter - May 27, 2026 Abbott's first dual-analyte sensor comes as competitors are working to develop their own versions of the technology. Read the full article | * Insulet recalls 7M patch pumps due to leak risk By Elise Reuter - May 27, 2026 The recall is Insulet's second this year related to tears in the device tubing. So far, 24 serious adverse events have been reported. Read the full article | * Beta Bionics to launch its first insulin patch pump to compete with Insulet By Elise Reuter - May 26, 2026 The device called Mint, which would work with the company's adaptive insulin dosing algorithm, is expected to debut in the first half of 2027. Read the full article | * Dexcom warns of scrapped glucose sensors being resold By Elise Reuter - May 26, 2026 Dexcom has identified two lots of G7 sensors that have been stolen, sold and used by customers. Read the full article | * Tandem to file tubeless insulin pump with FDA this quarter By Elise Reuter - May 8, 2026 The new version of Tandem's Mobi pump would be the diabetes technology company's first tubeless device. Read the full article | * MiniMed gets FDA nod for smaller insulin pump By Elise Reuter - March 18, 2026 MiniMed Flex is a smartphone-controlled insulin pump about half the size of MiniMed's previous device. It's the company's first launch since separating from Medtronic in early March. Read the full article | * Medtronic's MiniMed goes public for $560M By Elise Reuter - March 6, 2026 The diabetes tech business is now operating as a standalone, public company. Shares began trading on Friday. Read the full article | * FDA warns insulin infusion set maker Unomedical over leaks, mishandled complaints By Elise Reuter - March 2, 2026 Unomedical, which supplies diabetes tech firms including Medtronic, Tandem Diabetes Care and Beta Bionics, received more than 5,000 complaints about leaking infusion sets between 2023 and 2025. Read the full article | * FDA warns Beta Bionics on unreported complaints, insulin pump changes By Elise Reuter - Feb. 26, 2026 The Food and Drug Administration warning letter detailed unreported low blood sugar and a software change to correct for delayed glucose readings. Read the full article | * Abbott receives FDA warning letter over Freestyle Libre CGMs By Elise Reuter - Feb. 3, 2026 Abbott needs to conduct more performance testing to ensure its FreeStyle Libre devices are accurate, FDA inspectors found. Read the full article Filed Under: FDA

Yahoo Finance
Jun 2nd, 2026
Tandem Diabetes beats Q1 expectations with 5.5% revenue growth to $247M as pharmacy shift reshapes business model

Tandem Diabetes Care reported first-quarter revenue of $247.2 million, up 5.5% year over year, whilst shipping over 19,000 pumps in the US and 10,000 internationally. Gross margin expanded 482 basis points to 55.3%, and operating cash flow turned positive at $11.1 million versus a $21.2 million outflow last year. The company is shifting more US business towards a pharmacy-based, pay-as-you-go model, which can reduce near-term sales but lowers barriers for new pump users. Pharmacy sales represented 6% of US sales in Q1. Tandem's pump portfolio centres on Tandem Mobi and t:slim X2, both powered by Control-IQ closed-loop technology. The t:slim X2 offers remote feature updates, allowing users to stay current without full hardware replacement. Despite progress, TNDM shares fell 10.9% in Q1.

INACTIVE